Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1179470 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1179470 (Dose escalation) | EXPERIMENTAL | BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days. |
| BAY1179470 (additional) | EXPERIMENTAL | Additional cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days. |
| BAY1179470 (expansion) | EXPERIMENTAL | Expansion cohort: BAY1179470 will be administered as a 1-hour intravenous infusion every 21 days. |
| Name | Type | Description |
|---|---|---|
| BAY1179470 | DRUG | BAY1179470 will be administered as a 1-hour intravenous infusion. |
Inclusion Criteria: * Subjects with advanced, histologically or cytologically confirmed solid tumors refractory to any standard therapy or have no standard therapy available or subjects actively refuse any treatment which would be regarded standard * Eastern Cooperative Oncology Group (ECOG) perfor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY1179470 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed for patients with advanced, refractory solid tumors, meaning tumors that have not responded to prior treatments.
BAY1179470 is being developed by Bayer AG, a German multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker symbol BAYRY. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
BAY1179470 is in Phase 1 of clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial has been completed, and the drug is no longer in active clinical testing.
BAY1179470 has been studied in one clinical trial, identified as NCT01881217. This was a first-in-man dose escalation study in patients with advanced, refractory solid tumors. The trial was conducted in Japan, Singapore, and South Korea, enrolled 35 participants, and has been completed.
BAY1179470 is the only name provided for this investigational drug. No alternative names or aliases have been reported for this compound. It is a distinct small molecule being developed by Bayer AG for the treatment of neoplasms.